NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-16 |   Pages: 200+ |   Report ID: BYR-199697 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Next Generation Diabetes Therapy and Drug Delivery Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

7.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Abbott Laboratories

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Medtronic, Inc.

16.3 Sanofi

16.4 Novo Nordisk

16.5 MannKind Corporation

16.6 Enteris BioPharma

16.7 Dexcom, Inc.

16.8 Senseonics Holding, Inc.

16.9 Medtech

16.10 Johnson & Johnson

16.11 Synertech

16.12 Zosano Pharma Corp

16.13 Relmada Therapeutics

16.14 Eli Lilly and Company

16.15 Transdermal Specialties Inc

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Product Type
Inhalable Insulin
Oral Insulin
Insulin Patches
CGM Systems
Artificial Pancreas

By Demographic
Adult Population (>14years)
Child Population (14years)

By Indication
Type 1 Diabetes
Child Population (14years)

By End User
Diagnostic/Clinics
ICUs
Home Healthcare

Companies

Abbott Laboratories
Medtronic, Inc.
Sanofi
Novo Nordisk
MannKind Corporation
Enteris BioPharma
Dexcom, Inc.
Senseonics Holding, Inc.
Medtech
Johnson & Johnson
Synertech
Zosano Pharma Corp
Relmada Therapeutics
Eli Lilly and Company
Transdermal Specialties Inc

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.